Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851076 | 0.86 | DUT (0.41) | DUT | |
| SCHEMBL4936957 | 0.86 | DUT (0.41) | DUT | |
| SCHEMBL3062404 | 0.85 | DUT (0.39) | DUT | |
| SCHEMBL3596460 | 0.83 | DUT (0.38) | DUT | |
| SCHEMBL11580466 | 0.83 | DUT (0.42) | DUT | |
| SCHEMBL3114634 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL6444128 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL1535234 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL14673479 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL15954826 | 0.81 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062785-B | Preparation method of ozagrel and intermediate thereof | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-112062785-A | Preparation method of ozapimod and intermediate thereof | 广东东阳光药业有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250304604-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS SCIENTIFIC, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250215016-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai SIMR Biotechnology Co., Ltd (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506348-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simrd Biotechnology Co., Ltd (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-12180239-B2 | Organosilanes for the treatment of infections | TOPIKOS SCIENTIFIC, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12077552-B2 | Synthesis of fluoroalkyl tin precursors | ENTEGRIS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4402147-A1 | SYNTHESIS OF FLUOROALKYL TIN PRECURSORS | Entegris, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12006326-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-117957235-A | Synthesis of fluoroalkyl tin precursors | 恩特格里斯公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20110275849-A1 | PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES | BANNOU TADASHI | 2011-11-10 | — | — | US | disclosed |
| US-8008521-B2 | Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2105164-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20090082585-A1 | PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES | BANNOU TADASHI | 2009-03-26 | — | — | US | disclosed |
| US-7459577-B2 | Reacting a chlorosilane with grignard reagent | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20050070730-A1 | Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077552-B2 | Synthesis of fluoroalkyl tin precursors | NISCH, NACA, PNN | DUT 728/4885 |
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | DUT 1736/4885 |
| US-12180239-B2 | Organosilanes for the treatment of infections | ASNS, ACMSD, ARG1 | DUT 1854/4885 |
| US-20250304604-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | ASNS, ACMSD, ARG1 | DUT 1854/4885 |
| US-20250215016-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | GABRA5, GABRA1, CYP3A5 | DUT 3517/4885 |
| US-20110275849-A1 | PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES | MLX, HAX1, RPS4X | DUT 4759/4885 |
| US-20090082585-A1 | PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES | MLX, HAX1, RPS4X | DUT 4759/4885 |
| US-20050070730-A1 | Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes | MLX, HAX1, GRIA3 | DUT 4774/4885 |
| US-12006326-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | DUT 702/4885 |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | DUT 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.